Ascendis Pharma A/S $ASND Shares Bought by Aberdeen Group plc

Aberdeen Group plc increased its stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 81.4% during the third quarter, Holdings Channel.com reports. The fund owned 66,250 shares of the biotechnology company’s stock after buying an additional 29,738 shares during the period. Aberdeen Group plc’s holdings in Ascendis Pharma A/S were worth $15,094,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Chicago Partners Investment Group LLC boosted its holdings in Ascendis Pharma A/S by 2.3% in the third quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock valued at $564,000 after acquiring an additional 52 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the period. Fifth Third Bancorp lifted its position in shares of Ascendis Pharma A/S by 48.4% in the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 91 shares during the period. ProShare Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 5.6% in the 3rd quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 113 shares during the last quarter. Finally, AlphaCentric Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 2.6% in the 3rd quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company’s stock valued at $1,072,000 after purchasing an additional 121 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $271.19 on Wednesday. The company has a fifty day simple moving average of $242.71 and a 200 day simple moving average of $240.31. Ascendis Pharma A/S has a 12-month low of $188.08 and a 12-month high of $282.15. The company has a current ratio of 2.89, a quick ratio of 2.29 and a debt-to-equity ratio of 0.25. The company has a market cap of $16.92 billion, a P/E ratio of 17.72 and a beta of 0.40.

Wall Street Analysts Forecast Growth

ASND has been the subject of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday. Bank of America lowered their target price on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Wells Fargo & Company boosted their target price on shares of Ascendis Pharma A/S from $326.00 to $330.00 and gave the company an “overweight” rating in a report on Friday. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Sunday, November 8th. Finally, TD Cowen increased their price target on Ascendis Pharma A/S from $341.00 to $352.00 and gave the stock a “buy” rating in a report on Friday, November 13th. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus target price of $312.67.

Read Our Latest Stock Analysis on Ascendis Pharma A/S

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 40.00% of the company’s stock.

About Ascendis Pharma A/S

(Free Report)

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

Recommended Stories

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.